File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children

TitleEfficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children
Authors
Issue Date2015
Citation
Canadian Journal of Ophthalmology, 2015, v. 50, n. 3, p. 236-241 How to Cite?
Abstract© 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.Objective To evaluate the efficacy and safety of dexamethasone (DEX) intravitreal implant (Ozurdex) in pediatric patients with cystoid macular edema (CME) refractory to conventional treatment. Design This study is a retrospective chart review. Participants Four pediatric patients (5 eyes) with CME caused by uveitis, type I idiopathic macular telangiectasia (IMT), or Coats disease treated with DEX intravitreal implant. Methods Medical records of the 4 pediatric patients (5 eyes) with CME included in this study were reviewed. Data collected included details of the underlying diseases, treatments, and pretreatment and post-treatment central retinal thickness (CRT) measured by time-domain optical coherence tomography, visual acuity (VA), intraocular pressure (IOP), and lens status. The median follow-up time was 65 weeks (range, 59-93 weeks). Results Fifteen DEX intravitreal implants were injected into 5 eyes over the follow-up period. Reduction of CME was achieved in all eyes within 12 weeks after the initial injection. VA improved in 4 eyes and was unchanged in 1 eye at 12 weeks; VA improved in 2 eyes, decreased in 2 eyes, and was unchanged in 1 eye at 52 weeks. Three of 5 eyes experienced IOP elevation ≥10 mm Hg during the follow-up period. IOP was ultimately controlled medically in all eyes. Significant lens opacification was documented in 2 eyes. Conclusions DEX intravitreal implant can be considered as an effective adjunctive off-label treatment to pediatric macular edema caused by uveitis or IMT/Coats disease; the safety profile of repeated treatment is acceptable.
Persistent Identifierhttp://hdl.handle.net/10722/228220
ISSN
2015 Impact Factor: 1.46
2015 SCImago Journal Rankings: 0.685

 

DC FieldValueLanguage
dc.contributor.authorLei, Shaobo-
dc.contributor.authorLam, Wai Ching-
dc.date.accessioned2016-08-01T06:45:29Z-
dc.date.available2016-08-01T06:45:29Z-
dc.date.issued2015-
dc.identifier.citationCanadian Journal of Ophthalmology, 2015, v. 50, n. 3, p. 236-241-
dc.identifier.issn0008-4182-
dc.identifier.urihttp://hdl.handle.net/10722/228220-
dc.description.abstract© 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.Objective To evaluate the efficacy and safety of dexamethasone (DEX) intravitreal implant (Ozurdex) in pediatric patients with cystoid macular edema (CME) refractory to conventional treatment. Design This study is a retrospective chart review. Participants Four pediatric patients (5 eyes) with CME caused by uveitis, type I idiopathic macular telangiectasia (IMT), or Coats disease treated with DEX intravitreal implant. Methods Medical records of the 4 pediatric patients (5 eyes) with CME included in this study were reviewed. Data collected included details of the underlying diseases, treatments, and pretreatment and post-treatment central retinal thickness (CRT) measured by time-domain optical coherence tomography, visual acuity (VA), intraocular pressure (IOP), and lens status. The median follow-up time was 65 weeks (range, 59-93 weeks). Results Fifteen DEX intravitreal implants were injected into 5 eyes over the follow-up period. Reduction of CME was achieved in all eyes within 12 weeks after the initial injection. VA improved in 4 eyes and was unchanged in 1 eye at 12 weeks; VA improved in 2 eyes, decreased in 2 eyes, and was unchanged in 1 eye at 52 weeks. Three of 5 eyes experienced IOP elevation ≥10 mm Hg during the follow-up period. IOP was ultimately controlled medically in all eyes. Significant lens opacification was documented in 2 eyes. Conclusions DEX intravitreal implant can be considered as an effective adjunctive off-label treatment to pediatric macular edema caused by uveitis or IMT/Coats disease; the safety profile of repeated treatment is acceptable.-
dc.languageeng-
dc.relation.ispartofCanadian Journal of Ophthalmology-
dc.titleEfficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jcjo.2015.01.007-
dc.identifier.pmid26040225-
dc.identifier.scopuseid_2-s2.0-84930160239-
dc.identifier.volume50-
dc.identifier.issue3-
dc.identifier.spage236-
dc.identifier.epage241-
dc.identifier.eissn1715-3360-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats